Biopharma M&A activity scaled record highs in 2019, with a few mega mergers announced involving names such as Bristol-Myers Squibb Co, Roche Holdings AG Basel ADR and AbbVie Inc
It’s feared that the frenetic pace of M&A in the sector could slow down in the coming year.
Yet there are fundamental reasons to think otherwise: there could at least be many more bolt-on acquisitions as companies, especially cash-rich big pharma companies with an ageing pipeline, strive to reinvigorate slowing growth.
The upcoming year is likely to see many hostile deals, Evaluate Pharma reported, citing Steven Slaughter, managing director of Manulife Investment Management.
“There are enough interesting targets where management teams don’t want to sell, but in the large-cap world balance sheets are becoming so large they just have to deploy some capital,” Slaughter was quoted as saying at the Jefferies Healthcare Conference.
Increased scrutiny by regulators could serve as a dampener. In 2019, the FTC made several second requests, requiring additional information for vetting M&A transactions.
10 Biotech M&A Targets For 2020
The following are potential targets that could find themselves in the M&A mix in the coming year.
Gene editing company Crispr Therapeutics AG is speculated to be a potential target for Vertex Pharmaceuticals Incorporated , given the licensing agreement in place between the companies. Incidentally, Vertex itself is considered an M&A target.
Source: Yahoo Finance